康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购预计获最高约3.2亿美元收益

智通财经03-24

智通财经APP讯，康诺亚-B(02162)发布公告，本公司透过其全资附属公司一桥香港于Ouro Medicines的股本中持有约15%少数权益，该权益于本公司的综合财务报表中入账为以公允价值计量且其变动计入当期损益的金融资产。Ouro Medicines已知会本公司，于2026年3月23日，买方吉利德科学公司(Gilead Sciences, Inc.)已同意以并购方式收购Ouro ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621038311?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-24 06:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621038311","market":"sh","top_or_hot":-1,"title":"康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康诺亚-B(02162)发布公告，本公司透过其全资附属公司一桥香港于Ouro Medicines的股本中持有约15%少数权益，该权益于本公司的综合财务报表中入账为以公允价值计量且其变动计入当期损益的金融资产。Ouro Medicines已知会本公司，于2026年3月23日，买方吉利德科学公司(Gilead Sciences, Inc.)已同意以并购方式收购Ouro ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417737.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 06:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1417737.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康诺亚-B(02162)发布公告，本公司透过其全资附属公司一桥香港于Ouro Medicines的股本中持有约15%少数权益，该权益于本公司的综合财务报表中入账为以公允价值计量且其变动计入当期损益的金融资产。Ouro Medicines已知会本公司，于2026年3月23日，买方吉利德科学公司(Gilead Sciences, Inc.)已同意以并购方式收购Ouro ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417737.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417737.html","article_id":"2621038311","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621038311","pubTimestamp":1774306066,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"紧随完成后，本集团将不再持有Ouro Medicines的任何股权。截至2025年12月31日，本集团自其于Ouro Medicines的股权录得未变现公允价值收益100万美元。董事认为，并购协议乃由买方与Ouro Medicines按公平原则磋商达成，按正常商业条款订立，属公平合理，而并购协议条款及其项下拟进行的交易符合本公司及其股东的整体利益。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","02162":"康诺亚-B","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"Connoya-B (02162): The holding company Ouro Medicines was acquired by Gilead and is expected to earn up to about $320 million in revenue","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5},"content_text":"智通财经APP讯，康诺亚-B(02162)发布公告，本公司透过其全资附属公司一桥香港于Ouro Medicines的股本中持有约15%少数权益，该权益于本公司的综合财务报表中入账为以公允价值计量且其变动计入当期损益的金融资产。Ouro Medicines已知会本公司，于2026年3月23日，买方吉利德科学公司(Gilead Sciences, Inc.)已同意以并购方式收购Ouro Medicines。紧随完成后，本集团将不再持有Ouro Medicines的任何股权。并购协议规定，完成时的首付款为16.75亿美元(可按惯例调整)，且或有里程碑付款不多于5亿美元，总额最高可达21.75亿美元。董事认为，并购事项证实如CM336/OM336所展示的本集团同类最佳T细胞衔接器 (TCE)平台的巨大潜力。同时，此项交易将使本集团可加速推进CM336/OM336的全球开发进程，使其成为治疗多种有高度未满足需求的自身免疫性疾病的潜在同类最佳TCE，从而释放并扩大其全球市场价值。截至2025年12月31日，本集团自其于Ouro Medicines的股权录得未变现公允价值收益100万美元。本集团自并购事项产生的预期收益包括：(i)首付款约2.5亿美元;及(ii)或有里程碑付款不多于约7000万美元，总额最高可达约3.2亿美元，将取决于监管及业绩里程碑的达成情况而定。于本集团综合损益表入账的确实金额须待审核，因此可能与本公告所载数字有差异。该笔款项到账后将进一步充盈公司现金储备，用以快速推进核心产品的商业化和后续潜力管线的研发。与Ouro Medicines及Ouro Medicines Ltd(曾用名Platina Medicines Ltd，为Ouro Medicines的全资附属公司)就CM336/OM336的许可及未来研发而订立的独家许可协议将继续按其条款生效，而本集团将继续根据独家许可安排获得利益。本公司认为，并购事项将大幅提升CM336/OM336在全球市场的竞争地位。董事(包括独立非执行董事)认为，并购协议乃由买方与Ouro Medicines按公平原则磋商达成，按正常商业条款订立，属公平合理，而并购协议条款及其项下拟进行的交易符合本公司及其股东的整体利益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621038311","isCrawlerRequest":true}

康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益

精彩评论

康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购预计获最高约3.2亿美元收益